secukinumab + placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Psoriasis, Plaque-type Psoriasis
Conditions
Psoriasis, Plaque-type Psoriasis
Trial Timeline
Jan 1, 2012 → Dec 1, 2014
NCT ID
NCT01537432About secukinumab + placebo
secukinumab + placebo is a phase 2 stage product being developed by Novartis for Psoriasis, Plaque-type Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT01537432. Target conditions include Psoriasis, Plaque-type Psoriasis.
What happened to similar drugs?
20 of 20 similar drugs in Psoriasis, Plaque-type Psoriasis were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (19)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05722522 | Phase 3 | Terminated |
| NCT05758415 | Phase 3 | Terminated |
| NCT04737330 | Phase 3 | Terminated |
| NCT04732117 | Phase 3 | Completed |
| NCT04181762 | Phase 3 | Terminated |
| NCT04156620 | Phase 3 | Completed |
| NCT03713632 | Phase 3 | Completed |
| NCT03713619 | Phase 3 | Completed |
| NCT03055494 | Approved | Completed |
| NCT02896127 | Phase 3 | Completed |
| NCT02696031 | Phase 3 | Completed |
| NCT02599129 | Phase 2 | Terminated |
| NCT02594098 | Phase 2 | Completed |
| NCT02362789 | Phase 3 | Completed |
| NCT01989468 | Phase 3 | Completed |
| NCT02044848 | Phase 2 | Terminated |
| NCT01892436 | Phase 3 | Completed |
| NCT01807520 | Phase 3 | Completed |
| NCT01537432 | Phase 2 | Completed |
Competing Products
20 competing products in Psoriasis, Plaque-type Psoriasis